A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

Medicine, Oncology, Radiation Oncology +14

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin et al. · Blood · 1997 · 868 citations

Medicine, Geriatric Medicine, Oncology +8

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton et al. · Clinical Cancer Research · 2007 · 357 citations · Full text

Medicine, Oncology, Pharmacology +16

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity

Steven Howard, Valério Berdini, John A. Boulstridge et al. · Journal of Medicinal Chemistry · 2008 · 331 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14